Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management

Enrico Marinelli¹, Renata Beck², Antonio Malvasi³, Alfredo Fabrizio Lo Faro⁴, and Simona Zaami¹

¹ Department of Anatomical, Histological, Forensic, and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy
² Department of Anaesthesia, Santa Maria Hospital, GVM Care & Research, Bari, Italy
³ Department of Obstetrics and Gynaecology, Santa Maria Hospital, Bari, Italy
⁴ Section of Legal Medicine, Department of Excellence SBSP, University “Politecnica delle Marche” of Ancona, Ancona, Italy

[Received in July 2019; Similarity Check in July 2019; Accepted in March 2020]

Gamma-hydroxybutyrate (GHB) is a central nervous system depressant primarily used as a recreational drug of abuse, but also for the treatment of narcolepsy with cataplexy in adult patients and as an adjuvant for control of alcohol withdrawal syndrome. The main aim of this review is to summarise updated knowledge about GHB pharmacokinetics and pharmacodynamics, acute poisoning, and clinical features of GHB withdrawal syndrome, its diagnosis and medical treatment. The most common clinical signs and symptoms of acute poisoning include sleepiness to deep coma, bradycardia, hypotension, and respiratory failure. Therapy is essentially supportive and based on continuous monitoring of vital signs. GHB withdrawal syndrome shares patterns with other withdrawal syndromes such as alcohol withdrawal and is sometimes difficult to distinguish, especially if toxicological tests are GHB-negative or cannot be performed. There are no official detoxification protocols for GHB withdrawal syndrome, but its therapy is based on benzodiazepine. When benzodiazepine alone is not effective, it can be combined with barbiturates or antipsychotics. Information about abuse and distribution of GHB and its precursors/analogues among the general population is still limited. Their prompt identification is therefore crucial in conventional and non-conventional biological matrices, the latter in particular, to clarify all the issues around this complex molecule.

KEY WORDS: acute toxicity; GABA; gamma-aminobutyric acid; gamma-butyrolactone; 1,4-butanediol; GHB; pharmacodynamics; pharmacokinetics; withdrawal syndrome

As the issue of GHB abuse has been widespread and is still raising a number of questions, we wanted to put together all the updated information we know about its pharmacokinetics and pharmacodynamics, acute poisoning, and the clinical features of GHB withdrawal syndrome, its diagnosis, and medical treatment. We also wanted to provide some background information about GHB history, trends, and context of (ab)use.

LITERATURE SEARCH

Our Pubmed and Scopus search included a wide date span from 1970 to 2019 with the following key words: “gamma-hydroxybutyrate”, “gamma-butyrolactone”, “1,4-butanediol”, “GHB pharmacokinetics”, and “GHB pharmacodynamics” alone or in combination with “GHB acute toxicity” and “GHB withdrawal syndrome”. Besides these two databases, we also ran an Internet search that returned several books, non-indexed sources, and institutional websites. Of the 1,150 sources found, we excluded 305 duplicates. We then checked the remaining 845 to see if they matched our interests. Only 55 papers

Corresponding author: Renata Beck, MD, Department of Anaesthesia, Santa Maria Hospital, GVM Care & Research, Via Antonio de Ferraris 22, 70124 Bari, Italy, E-mail: beckrenata64@gmail.com
were considered appropriate for this review. All were written in English and were original research articles or reviews.

GHB TRENDS, CONTEXT OF USE, AND FORENSIC TOXICOLOGY ISSUES

Information about the trends of GHB use (including GHB analogous/precursors) among general population is limited, unlike with many other drugs (8). A recent report by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (9) says that the consumption of GHB and its analogues/precursors is generally low in Europe, save for particular contexts such as gay nightclubs (10–13). In this context of chemsex, GHB is frequently combined with synthetic cathinones (14) and other new psychoactive substances. It is a risky practice that has been reported for acute poisoning and even fatalities (15).

According to the Independent Drug Monitoring Unit (IDMU) report in 2003 (16), GHB use peaked between 1994 and 2002, and before 1990 very few people used it. GHB and its analogues/precursors are usually taken by young adults aged between 19 and 22, who had tried many other substances before (16, 17). Another US study (18) reports a steady decline in GHB use from 2000 (the year in which GHB was declared illegal in the US) to 2008.

Even so, the issue of high mortality risk remains. GHB and its precursors/analognes are commonly detected in ante and post-mortem conventional and non-conventional biological matrices (mainly vitreous humour, hair, and nails) (19) by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) and gas chromatography tandem mass spectrometry (GC-MS/MS) (20, 21). Cases of GHB adulteration have most often been reported in connection with chemsex (22, 23). Taking into account that this compound is both endogenous and exogenous, cut-offs play a key role in distinguishing between the two. In samples taken from living subjects these are 5 mg/L for blood and 10 mg/L for urine, whereas in post-mortem specimens they are 30 mg/L and 50 mg/L for peripheral and central blood, respectively and 10 mg/L for urine (24, 25).

GHB HISTORY

The first case of GHB synthesis dates back to 1874 and was reported by A. Zaytseff (26). Pioneering research on the effects of GHB in humans was led by Dr Laborit in the early sixties (25). In 1964, GHB was used as an anaesthetic, but has not taken root because of the considerable number of adverse effects. From the 1970s to 1980s, many cases of GHB abuse were reported among body builders for its alleged potential to increase growth hormones (27). Throughout the 1980s and 1990s, it gained notoriety as a stimulant of sexual performance, especially among regular nightclub goers (1, 2). Since the 1990s, GHB has gained more attention because of numerous cases of acute poisoning. In 2000, the US Drug Enforcement Agency (DEA) included GHB in Schedule I of drugs due to its potential for abuse and for physical and psychological dependence. In 2003, it was listed as a Class C drug in the UK Misuse of Drugs Act.

As a drug of abuse, GHB is under control in all the EU member states. However, it has also found application in the treatment of narcolepsy and less frequently as an adjuvant in the control of alcohol withdrawal syndromes and alcohol dependence (2, 28, 29).

GHB PHARMACODYNAMICS

GHB is both GABA precursor and metabolite and a neuromodulator in the GABA system. Neurons that release GABA are mostly localised in the hippocampus, cortex, and amygdala, which is where G protein-coupled receptors (GPCRs) (30, 31) are also located in pre and post-synaptic
cells. After endogenous release, GHB binds to these receptors. However, to bind to the GABA-B receptor and exert its adverse effects, it must reach much higher levels obtained only with exogenous administration, because GHB is in fact a weak GABA-B agonist.

Its high affinity for receptors other than GABA-B has explained some of its pharmacological effects such as GHB-induced cataplexy in certain animal studies because of the involvement of N-methyl-D-aspartate (NMDA) receptors (32, 33).

GHB can also affect other neurotransmitter systems such as serotonergic and more notably dopaminergic. Some studies show that, after initial inhibition of dopamine release, GHB increases its production in a dose-dependent manner (33–36).

GHB PHARMACOKINETICS

Absorption

GHB shows good absorption after oral administration. In a study with eight male healthy volunteers receiving 12.5, 25, and 50 mg/kg of GHB (29) its time to reach maximum blood concentration (T_{max}) ranged between 20 and 60 min and correlated with the dose (25, 30, and 45 min in average, respectively). On the other hand, the maximum blood concentration achieved (C_{max}) did not vary considering the received doses (23, 23, and 20 µg/mL respectively), which suggests that GHB absorption is limited.

In another study with 12 healthy volunteers (six men and six women) (30) who received a single 25 mg/kg dose of GHB mean urine T_{max} was 1 h and C_{max} 67.6 µg/mL, whereas blood T_{max} was 24.6 min and C_{max} 48.0 µg/L.

Distribution

The mean volume of distribution varies from 192 to 741 mL/kg in healthy volunteers and from 225.9 to 307 mL/kg in patients with narcolepsy and liver failure (37–39). No significant variations have been observed between the sexes or associated with concomitant food intake. GHB can cross the placental barrier. Its capacity of binding plasma proteins is reduced.

Metabolism

Over 90% of the administered dose of GHB undergoes hepatic metabolism by several enzymatic pathways and is closely related to GABA metabolism. The main route is oxidation by GHB dehydrogenase to produce succinic semialdehyde, which is further oxidised into succinic acid. Further metabolism via the Krebs cycle transforms it into carbon dioxide and water (Figure 2) (37–39).

Excretion

According to many animal studies, GHB excretion is non-linear. The same was observed in the eight volunteers after oral administration of a therapeutic GHB dose (29).

In the study with 12 healthy volunteers referred to above (30), urinary GHB concentration dropped below the endogenous cut-off of 5 mg/L in eleven of them six hours after administration, which suggests that only a small percentage (from 0.6 to 2.5%) is excreted in urine (35–37).

ACUTE POISONING WITH GHB

Clinical presentation

Acute GHB poisoning can pose a medical challenge because it starts with unspecific symptoms shared by other acute poisonings with depressants.

In a retrospective study of 88 patients (61 men and 27 women, mean age 28 years) treated for acute GHB poisoning 59 ingested other substances as well, mainly alcohol (34 patients) and amphetamines (25 patients). In 53 patients the Glasgow Coma Scale (GCS) score was below 9. Of them, 25 patients had the GCS score 3 and 28 from 4 to 8 (39). The most common clinical signs were bradycardia (present in almost all patients with the GCS score under 8), frequently accompanied by hypotension, then hypothermia (21 patients), and acute respiratory acidosis. Tachycardia and hypertension were early clinical manifestations, usually occurring 15–30 min after ingestion (39). Almost all patients regained consciousness spontaneously within five hours of GHB ingestion.

Figure 2 Synthesis of GABA from glutamate and metabolism into succinic semialdehyde or GHB (adapted from reference 37)
There where GHB is taken with other substances, clinical presentation and management require more attention, because these other substances can “mask” some of the symptoms (2, 40).

Considering that GHB is a depressant acting on the central nervous system, the effects of acute poisoning can range from sleepiness to deep coma. They usually occur 15–50 minutes after ingestion and are short lived, which mainly depends on the dose. In most cases, neurological effects resolve within six hours. As a rule, management is supportive (29).

Table 1 shows neurological symptoms of acute GHB poisoning.

The most common respiratory manifestation is bradypnoea, which is often accompanied by type 2 respiratory failure.

The most common gastrointestinal symptoms are vomiting (present in 20–55 % of cases, as reports vary in this respect), abdominal pain, and sialorrhoea (40–43).

**Determination and treatment**

To distinguish between exogenous and endogenous GHB, a threshold commonly used for samples taken from living patients is 10 mg/L in urine, and 5 mg/mL in blood. GHB is not stable in either and its concentration increases with time after sampling. In post-mortem blood, endogenous GHB concentrations can be much higher (see above) (44–47).

There are many methods for GHB detection in urine and blood. The most common is gas chromatography (GC) coupled with mass spectrometry (MS) or flame ionisation detection (FID). In addition, a number of liquid chromatography tandem mass spectrometric (LC-MS/MS) methods have recently been developed, which detect GHB after solid phase extraction (SPE) (48–50).

Therapy is essentially supportive and based on continuous monitoring of vital signs. Particular attention is paid to the cardiovascular and respiratory symptoms described earlier in the text.

Intubation is indicated in unconscious patients who are vomiting to prevent aspiration and choking.

Many substances such as (naloxone, flumazemil, or GABA antagonist have been tried as potential antidotes, but there is no sufficient scientific evidence to support their routine application (51–55).

**Table 1 Neurological symptoms of acute GHB poisoning**

| Very common symptoms                                              | Common symptoms                                                                 | Less common symptoms                                                                 |
|-------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Ataxia, disorientation, dizziness, confusion, hallucinations,    | Dysarthria, confusion, headache, incoordination, euphoria, amnesia, hypotonia,   | Bruxism, vertigo, disinhibition, increased sexual arousal, delusions, extrapyramidal |
| somnolence, slurred speech, myosis                                | hyporeflexia, tremor, myoclonus, horizontal and vertical gaze nystagmus           | side effects, dystonias, athetosis, mydriasis                                        |

**GHB WITHDRAWAL SYNDROME**

**Clinical presentation**

The clinical presentation of GHB withdrawal syndrome is similar to other withdrawal syndromes, alcohol and benzodiazepine in particular. This is the reason why it can sometimes be very difficult to distinguish between them, especially if GHB tests are negative or could not be run (4, 60–63).

Considering the limited time of GHB action and its rapid elimination, signs and symptoms of GHB withdrawal syndrome soon become apparent, usually within 1–6 h after the last administration.

The withdrawal symptoms, however, can last for quite a while, 14 days or even more. They include anxiety, different degrees of depression, cognitive deficits, persistent insomnia, tremor, and tachycardia, which is often accompanied by hypertension. Other common clinical manifestations include confusion, disorientation, and paranoia. They usually last between three and 21 days (58).

Most people with dependency have been taking GHB and/or its analogues/precursors for less than two years, and the first manifestations appear as soon as 8–13 weeks into the use.

In a retrospective study (59) of eight patients with chronic GHB use, the first clinical manifestations of withdrawal appeared as quickly as 1–6 h after the administration of the last dose, and symptoms lasted between 5 and 15 days. Within 24 h from the last dose manifestations included severe anxiety and insomnia, moderate nausea, and vomiting. In the following five days, anxiety and insomnia continued, accompanied by delirium, confusion, and visual hallucinations. Seven to 15 days after the last dose, moderate anxiety, confusion, insomnia, and visual hallucinations persisted only episodically. Delirium was more frequent in patients who had been taking GHB every 30 min to 8 h than in those taking it every 1–24 h.

**Management and therapy**

Case studies presented in medical literature provide general guidelines based on experience and common symptoms with other withdrawal syndromes, but there are no formal detoxification protocols for GHB or its analogues. Withdrawal therapy is based on benzodiazepine and when benzodiazepine alone is not effective against severe
After ingestion and absorption in the gastrointestinal tract GBL rapidly metabolises into GHB by lactonase enzymes in the blood. GBL-naïve users could have a delayed or weakened effect of GHB, whereas people who have already taken this drug will experience the normal full effects due to increased production of lactonase enzymes (65, 66).

GBL is more lipophilic, more quickly absorbed by the gastrointestinal tract, and more bioavailable than its active metabolite GHB. These pharmacokinetic properties make GBL more potent and faster than GHB, but its effects last less time (65–67).

**CONCLUSION**

Information about GHB/precursor/analogue use and their distribution among the general population is limited. What we know is that it is used alone or in combination with other substances such as sexual and cognitive enhancers, new psychoactive substances, and alcohol (22, 68, 69). Their prompt identification is therefore crucial in conventional and non-conventional biological matrices, the latter in particular (70, 71) to clarify all the issues around this complex molecule.

**REFERENCES**

1. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol 2012;50:458–70. doi: 10.3109/15563650.2012.702218
in healthy volunteers. Eur J Clin Pharmacol 1993;45:353–6. doi: 10.1007/bf0265954

31. Cypers E, Flanagan RJ. The interpretation of hair analysis for drugs and drug metabolites. Clin Toxicol 2018;56:90–100. doi: 10.1080/15563650.2017.1379603

32. Pargst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta 2006;370:17–49. doi: 10.1016/j.cca.2006.02.019

33. Ferrara SD, de Inverno G, Frison G, Orlando R, Mazzo M, Zordan R, Padroni R, Palatini P. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Eur J Clin Pharmacol 1996;50:305–10. doi: 10.1007/s00220050113

34. Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980;6:93–9. PMID: 7449723

35. Etolin AA. Determination of endogenous gamma-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev 2012;36:1217–27. doi: 10.1016/j.neubiorev.2012.02.002

36. Huestis MA. Intra- and interindividual variations in urinary gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998;91:56–7. PMID: 9617031

37. van Amsterdam JGC, Brunt TM, McMaster MTB, Niesink RJM. Possible long-term effects of gamma-hydroxybutyrate (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev 2012;36:1217–27. doi: 10.1016/j.neubiorev.2012.02.002

38. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007;81:178–84. doi: 10.1038/sj.clpt.6100037

39. van Noorden MS, van Dongen LCAM, Zitman FG, Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal delirium: a case report and literature review. J Emerg Med 2000;18:65–70. doi: 10.1016/s0736-4679(99)00163-8
Zloporaba gama-hidroksibutirata – farmakologija, trovanje i liječenje ovisnosti

Gama-hidroksibutirat (GHB) depresiv je središnjega živčanog sustava koji se ponajviše zlorabi kao rekreativna droga, ali se primjenjuje i za liječenje narkolepsije s katapleksijom u odraslih bolesnika te kao pomoćni lijek u kontroli sindroma odvikavanja od alkohola. Ljudi i endogeno proizvode GHB, budući da je on prekursor gama-aminomaslačne kiseline (GABA), jednoga od glavnih neurotransmitera s inhibicijskim učinkom na živčani sustav. GHB ima ulogu neuromodulatora u GABA sustavu i uglavnom djeluje preko GABA-B receptora. Za zloporabu se čestu kupuju GBH prekursori/analozi gama-butirolakton (GBL) i 1,4-butanediol (1,4-BD) u obliku otapala namijenjenih legalnoj industrijskoj uporabi. Oni, međutim, nisu endogeni. Glavni je cilj ovoga preglednog rada bio sažeti najnovije spoznaje o farmakokinetici i farmakodinamici GHB-a, akutnom trovanju i o kliničkim značajkama sindroma odvikavanja od GHB-a, njegovoj dijagnozi i liječenju. Akutno je trovanje GHB-om donekle i dijagnostički izazov jer su znakovi i simptomi uobičajeni i za depresive središnjega živčanog sustava. Najčešći su klinički znakovi akutnoga trovanja pospanost (sve do duboke kome), bradikardija i hipotenzija te respiratorno zatajenje. Liječenje je u osnovi potporno, uz stalno praćenje vitalnih znakova. Sindrom odvikavanja od GHB-a dijeli značajke s drugim sindromima odvikavanja (npr. od alkohola ili benzodiazepina). Ponekad ih je vrlo teško razlikovati, ponajviše kada su testovi na GHB negativni ili nije moguće napraviti toksikološku analizu. Ne postoje službeni protokoli za detoksikaciju od GHB-a ili njegovih prekursora/analoga. Liječenje se temelji na primjeni benzodiazepina te, ovisno o težini simptoma, sekundarno barbituratima ili antipsihoticima.

KLJUČNE RIJEČI: akutna toksičnost; GABA; gama-aminomaslačna kiselina; gama-butirolakton; 1,4-butanediol; GHB; farmakodinamika; farmakokinetika; sindrom odvikavanja